SCHEMBL324120

SCHEMBL324120

O=C(OCc1ccc(Cl)cc1)N1C=Cc2ccccc2C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX4 Q99571 2/20 0.46
HSD17B3 P37058 1/20 0.41
L3MBTL1 Q9Y468 4/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
ALDH1A1 P00352 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
KMT2A Q03164 4/20 0.38
MEN1 O00255 3/20 0.38
MAPT P10636 3/20 0.38
POLB P06746 2/20 0.38
GAA P10253 1/20 0.38
THRB P10828 1/20 0.37
MMP1 P03956 1/20 0.37
MMP2 P08253 1/20 0.37
MMP9 P14780 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL324299 0.90 P2RX4 (0.52) P2RX4L3MBTL1NPC1RAB9AALDH1A1
SCHEMBL324346 0.89 P2RX4 (0.47) P2RX4L3MBTL1NPC1RAB9AALDH1A1
SCHEMBL324380 0.88 P2RX4 (0.42) P2RX4L3MBTL1NPC1RAB9AKMT2A
SCHEMBL325206 0.87 HCAR2 (0.43) P2RX4HSD17B3L3MBTL1NPC1RAB9A
SCHEMBL324667 0.85 P2RX4 (0.48) P2RX4NPC1RAB9AALDH1A1MAPT
SCHEMBL324069 0.84 MMP12 (0.40) P2RX4L3MBTL1NPC1RAB9AMMP1
SCHEMBL325232 0.83 HSD17B3 (0.46) HSD17B3PTGDR2
SCHEMBL323930 0.83 HSD17B3 (0.46) HSD17B3L3MBTL1CYP1A2CYP3A4CYP2C9
SCHEMBL324441 0.83 HSD17B3 (0.43) HSD17B3TDP1PTGDR2
SCHEMBL324263 0.82 L3MBTL1 (0.40) P2RX4HSD17B3L3MBTL1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590944-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS Actelion Pharmaceuticals Ltd. (CH) 2013-05-15 EP disclosed
US-20130109685-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD. (CH) 2013-05-02 US disclosed
WO-2012004722-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109685-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS PTGER1, PTGDR, PTGDR2 P2RX4 88/4885HSD17B3 967/4885L3MBTL1 4628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.